Altimmune(US:ALT) prnewswire.com·2024-05-23 00:45Core Viewpoint - Rosen Law Firm is reminding investors who purchased Altimmune, Inc. securities during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1] Group 1: Class Action Details - The class period for the Altimmune securities is from December 1, 2023, to April 26, 2024 [1] - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties must move the Court by July 5, 2024, to serve as lead plaintiff [1][4] Group 2: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company [2] - The firm was ranked No. 1 for securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions for investors [2] - In 2019, the firm secured over $438 million for investors, showcasing its effectiveness in litigation [2] Group 3: Allegations Against Altimmune - The lawsuit alleges that Altimmune made false and misleading statements regarding its lead product candidate, pemvidutide, particularly in relation to its efficacy and tolerability compared to competitors [3] - It is claimed that the results from the MOMENTUM trial were less significant than represented, impacting Altimmune's commercial prospects [3] - The lawsuit asserts that these misrepresentations led to an overstatement of Altimmune's potential for finding a strategic partner for pemvidutide [3]